Effects of didanosine-related depletion of mtDNA in human T lymphocytes

Journal of Infectious Diseases

Volumn 191, Issue 6, 2005, Pages 848-855

  Setzer, B ^a   Schlesier, M ^a   Walker, Ulrich A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD28 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYTOCHROME C OXIDASE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; INTERLEUKIN 2 RECEPTOR ALPHA; LACTIC ACID; MITOCHONDRIAL DNA; MONOCLONAL ANTIBODY CD3; PROTEIN SUBUNIT; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL MEMBRANE DEPOLARIZATION; CELL VACUOLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FUNCTIONAL DISEASE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; UPREGULATION;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIDANOSINE; DNA, MITOCHONDRIAL; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES;

EID: 14844286857     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427655     Document Type: Article

References (30)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-44.
3. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-22.
4. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-38.
5. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-73.
6. Walker UA, Bäuerle J, Laguno M, et al. Antiretroviral therapy with ddI, d4T or ddC is associated with depletion of mitochondrial DNA in liver. Antivir Ther 2003; 8:L15-6.
7. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′- Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N Engl J Med 1990; 322:1333-40.
8. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-20.
9. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70:497-505.
10. Cote HC, Yip B, Asselin JJ, et al. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187:1972-6.
11. Miro O, Lopez S, Pedrol E, et al. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003; 8:333-8.
12. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16:513-8.
13. Cossarizza A, Pinti M, Moretti L, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 2002; 185:299-305.
14. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003; 16:5-10.
15. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20(2):143-8.
16. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002; 105:259-72.
17. Hammond EL, Sayer D, Nolan D, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; 27:97-110.
18. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30:271-7.
19. Löffler M, Jöckel J, Schuster G, Becker C. Dihydroorotate- ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997; 174:125-9.
20. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47:273-89.
21. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275:1043-9.
22. Silva HT, Cao W, Shorthouse R, Morris RE. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc 1996; 28:3082-4.
23. French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials 2002; 3:177-85.
24. Molina JM, Chene G, Ferchal F, et al. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis 1999; 180:351-8.
25. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991; 87:1916-24.
26. Foli A, Benvenuto F, Piccinini G, et al. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001; 15:1687-94.
27. Tolomeo M, Mancuso S, Todaro M, et al. Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy. J Clin Pathol 2003; 56:147-51.
28. Polo R, Martinez S, Madrigal P, Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr 2003; 34:32-6.
29. Negredo E, Moltó J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-63.
30. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-95.